Monthly Archives: November 2013

Two Incompatible Truths

There is major news regarding the neurotherapeutics aspirations for two Big Pharmas, Roche and Bristol Myers Squibb. Roche has had sufficient success in two of the three programs whose outcome was to dictate their future course vis-a-vis CNS (gantenerumab and … Continue reading

Posted in Big Pharma, BioFollies | Tagged , , | Leave a comment

Teva in Turmoil

Back in January, Teva Pharmaceuticals had made our Best News of 2012 roster, based on its announced intention to revamp and refocus its R&D on CNS and respiratory disorders, and to invest $10 billion over the next five years to … Continue reading

Posted in Big Pharma, BioFollies | Tagged , , | Leave a comment